SCHEMBL860324

SCHEMBL860324

Cc1nccn1-c1cccc(Nc2ccn3ncc(/C=C4/SC(=O)NC4=O)c3n2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 4/20 0.53
GAA P10253 4/20 0.53
SI P14410 4/20 0.53
MGAM2 Q2M2H8 4/20 0.53
CSNK2A2 P19784 3/20 0.47
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
POLB P06746 1/20 0.38
PIM1 P11309 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
NR1H4 Q96RI1 3/20 0.37
GLS O94925 2/20 0.37
GLS2 Q9UI32 1/20 0.37
MTOR P42345 3/20 0.36
PPARA Q07869 1/20 0.36
SYK P43405 1/20 0.36
CISD1 Q9NZ45 2/20 0.36
PIK3CG P48736 2/20 0.36
PIK3CD O00329 1/20 0.35
MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12978956 1.00 MGAM (0.53) MGAMGAASIMGAM2CSNK2A2
SCHEMBL860325 1.00 MGAM (0.53) MGAMGAASIMGAM2CSNK2A2
SCHEMBL861503 0.84 PIM1 (0.49) MGAMGAASIMGAM2NPC1
SCHEMBL12978877 0.84 PIM1 (0.49) MGAMGAASIMGAM2NPC1
SCHEMBL861502 0.84 PIM1 (0.49) MGAMGAASIMGAM2NPC1
SCHEMBL861602 0.83 CSNK2A2 (0.53) CSNK2A2PIM1SYKPIK3CGMAOB
SCHEMBL3483094 0.82 NR1H4 (0.43) MGAMGAASIMGAM2NPC1
SCHEMBL12978963 0.82 NR1H4 (0.43) MGAMGAASIMGAM2NPC1
SCHEMBL3483095 0.82 NR1H4 (0.43) MGAMGAASIMGAM2NPC1
SCHEMBL14679085 0.81 CSNK2A2 (0.44) MGAMGAASIMGAM2CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
EP-2432473-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS Cylene Pharmaceuticals, Inc. (US) 2012-03-28 EP disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010135581-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM1, PIM2, PIM3 MGAM 3831/4885GAA 2737/4885SI 3769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.